Mentha Capital expands in occupational health and safety services through its acquisition of ENRGY

Mentha

Investor Mentha Capital has acquired the shares of ENRGY in Business Group. At the start of 2020, Mentha established its position in the market with a majority stake in paraDIGMA Groep. Both companies, operating in the field of absenteeism and sustainable employability, will continue to operate under their own brand name, services, organisation and locations. The transaction is subject to the approval of the Dutch Healthcare Authority (NZa).

ENRGY is a fast-growing health and safety service, and with 200 professionals, helps its clients as a strategic and executive partner in structurally reducing absenteeism. In its services, ENRGY places a strong emphasis on the variables that determine sustainable work ability, summarised in The House of Work Ability. The founders and directors Marcel Houtman, Hidde Froentjes and Martijn ten Bokum will remain actively operationally involved and become co-shareholders in the Group Holding over ENRGY and paraDIGMA.

Marcel Houtman, ENRGY: “We are very pleased to have taken this step. Mentha can properly support us in continuing our growth and innovation ambitions, while our strong culture and vision is maintained. This enables us to build on our ultimate dream to allow the entire working Netherlands to take control of work capacity, with reduced absenteeism and increased job satisfaction as the goal. We believe that with the attractive propositions, knowledge and expertise of both companies, we are creating a powerhouse of innovation, in order to be able to respond to the rapidly changing market and to enhance the service we provide to our customers and clients.”

paraDIGMA Groep is a distinctive group of companies operating in the field of sustainable employability, active through a nationwide network and more than 600 employees. The Working Conditions Service division (De Arbodienst) is an occupational health and safety service provider with an unconventional view on absenteeism, which leads to progressive and highly effective absenteeism and health policies within organisations. The other components offer, among other things, psychological interventions, outplacement and reintegration, work-related research and advice, and company training. The company was founded in 2003 by Rudo Vissers, who is still active as managing director of paraDIGMA Groep and co-shareholder of the group holding.

Rudo Vissers, paraDIGMA Groep: “We are impressed by the solid position which ENRGY has attained in the market in recent years. From their own unique approach, ENERGY and paraDIGMA share a common vision on the subject of work and health. Both companies realise the great importance of culture and leadership in organisations in increasing employability and structurally reducing absenteeism, and proritise a high-quality medical basis and personal attention for clients.”

Mentha Capital invests in established, profitable companies which demonstrate clear potential for further expansion through organic growth, expansion into new markets and/or acquisitions. Mentha has 15 participating interests, active in various end markets.

Barend Rutten, Mentha Capital: “We are pleased to enter into a partnership with ENRGY. Sustainable employabiity is an increasingly important theme for companies and society at large. The market is in full swing and provides many opportunities. Mentha is happy to assist both companies in fulfilling their organic and acquisitive growth ambitions.”

MedPharm Announces Expansion of Formulation Development and Analytical Service Labs in the UK

Ampersand

MedPharm Ltd, the world leader in formulation development and analytical services for topical and transdermal products, is thrilled to announce a £1.5M investment into the refurbishment and expansion of our 15,000 sq ft campus in Surrey, UK that will increase our UK laboratory space by 35%.

With a planned increased presence of automated technologies stemming from this £1.5M investment, this new technology will help build upon and further support MedPharm’s position in the pharmaceutical formulation development and testing sectors for topical and transdermal drug delivery products.

Scheduled to be completed during the fourth quarter of 2021, the increased capacity will allow MedPharm to continue meeting the growing demand for its topical and transdermal services.

Dr Rob Turner, General Manager UK, MedPharm comments that the expansion and refurbishment of the laboratory space will allow a more streamlined workflow – providing an optimal service our clients can benefit from for many years to come.

Dr. Rob Turner“We are excited to be renovating our formulation development and analytical laboratories, clinical manufacturing suites and personnel workspace to ensure our operations and capabilities remain state of the art.”, commented Dr Rob Turner, General Manager UK.

“During the renovations, we will take extensive steps to de-risk the process and do not expect any disruption to our existing services, quality of scientific deliverables and client commitments throughout the refurbishment.”

“MedPharm has been supporting clients from Guildford for 15 years and this renovation will secure our footprint here in Surrey for years to come.”



About MedPharm

MedPharm is the world’s leading contract provider of topical and transdermal product design and formulation development services. MedPharm is experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through their unique, cost-effective and industry-leading performance testing models. Well established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm can also offer innovative solutions for ophthalmic and airway preparations recognized for their scientific rigor by regulators and investors. MedPharm has fully established Centers of Excellence in the USA and the UK.

Categories: News

Tags:

AEVIS VICTORIA SA acquires the remaining 80% of the share capital of Klinik Pyramide am See AG and integrates it into its subsidiary Swiss Medical Network


Press release

Fribourg, 18 May 2021

AEVIS VICTORIA SA acquires the remaining 80% of the share capital of Klinik Pyramide am See AG and integrates it into its subsidiary Swiss Medical Network

AEVIS VICTORIA SA (AEVIS) today signed an agreement with the physician shareholders of Klinik Pyramide am See AG to acquire the remaining share capital of the Zurich-based private hospital. This participation will be integrated into its subsidiary Swiss Medical Network SA, which already held a 20% stake in Klinik Pyramide am See AG since 2011. With around 120 employees and 80 physicians, Pyramid Clinic achieved revenues of CHF 18 million and an EBITDAR of CHF 3.6 million in 2020. The transaction will be carried out primarily through a share exchange and Klinik Pyramide am See AG will be consolidated into AEVIS from 1 July 2021.

For further information:
AEVIS VICTORIA SA Media and Investor Relations: c/o Dynamics Group, Zurich
Philippe R. Blangey, prb@dynamicsgroup.ch, +41 (0) 43 268 32 35 or +41 (0) 79 785 46 32
Séverine Van der Schueren, svanderschueren@aevis.com, +41 (0) 79 635 04 10

AEVIS VICTORIA SA – Investing for a better life
AEVIS VICTORIA SA invests in healthcare, hospitality & lifestyle and infrastructure. AEVIS′s main shareholdings are Swiss Medical Network SA (90%), the only Swiss private network of hospitals present in the country’s three main language regions, Victoria-Jungfrau AG, a luxury hotel group managing nine luxury hotels in Switzerland, Infracore SA (30%, directly and indirectly), a real estate company dedicated to healthcare-related infrastructure, a hospitality real estate division, Medgate (40%), the leading telemedicine provider in Switzerland, and NESCENS SA, a brand dedicated to better aging. AEVIS is listed on the Swiss Reporting Standard of the SIX Swiss Exchange (AEVS.SW). www.aevis.com.

 


End of ad hoc announcement


show this

Categories: News

Tags:

Lightyear Capital, Oak HC/FT, and Greater Sum Ventures Close on Sale of Therapy Brands to KKR

Lightyear
05.18.2021

New York, NY – May 18, 2021 – Lightyear Capital LLC (“Lightyear”), Oak HC/FT, and Greater Sum Ventures (“GSV”) today announced that investment funds affiliated with Lightyear, Oak HC/FT, and GSV have completed the sale of Therapy Brands to KKR. Financial terms were not disclosed. Funds affiliated with Lightyear and Oak HC/FT acquired a majority stake in Therapy Brands in July 2018.

Therapy Brands provides practice management, integrated patient payments, revenue cycle management, patient engagement, tele-health and data management solutions for mental and behavioral health practices to support their clinical, administrative and billing needs. The Therapy Brands suite of software tools enables more than 28,000 practices in psychotherapy, applied behavioral analysis, substance use recovery and physical therapy to streamline their practices and focus on their patients.

“We are delighted with the outcome of our investment in Therapy Brands,” said Mark F. Vassallo, Managing Partner of Lightyear Capital. “Over the course of our investment, Therapy Brands tripled in size, completing nine strategic acquisitions, increasing its client base, growing revenue by cross-selling value-added solutions and doubling its payments penetration. Our experience with Therapy Brands further supports our pursuit of attractive investment opportunities in embedded payments models as we see tremendous demand across a number of fast-growing verticals. We wish Kimberly and the entire team at Therapy Brands great continued success.”

“Oak HC/FT’s investment in Therapy Brands highlights our dual aim of backing tech-enabled companies that are increasing the quality and lowering the cost of healthcare,” said Andrew Adams, Co-Founder and Managing Partner of Oak HC/FT. “We are proud of all that Therapy Brands – led by a dedicated team – has accomplished and we’re looking forward to seeing how the company continues to innovate at a time when mental and behavioral health care is more in demand and important than ever.”

“We are pleased with the success of our investment in Therapy Brands,” said Ross Croley, CEO and Founder of GSV. “From the platform’s inception, we’ve provided strategic guidance to the management team on acquisitions and operations, and it’s exciting to see the execution and outcome of our thesis.”

“I want to thank the entire Therapy Brands team for their invaluable support and investment to drive client growth, adoption of our value-added solutions and expand our portfolio,” said Kimberly O’Loughlin, CEO of Therapy Brands. “While we are excited about partnering with KKR on our next chapter of growth, we are grateful to Lightyear, Oak HC/FT and GSV for their support in enabling our success.”

William Blair and TripleTree acted as financial advisors and Davis Polk & Wardwell LLP as legal advisor to Therapy Brands.

About Therapy Brands
At a time when the topics of digital connectivity and access to care are at the forefront of the cultural conversation in the U.S., Therapy Brands is equipping practitioners with effective solutions to address the growing needs of mental and behavioral health, substance use recovery, applied behavior analysis and rehabilitation populations. Through purpose-built, fully integrated practice management and HER solutions provided by Therapy Brands, healthcare providers can improve patient quality of care and support better health outcomes for those they serve. Therapy Brands is headquartered in Birmingham, AL. For more information, please visit us at: https://www.therapybrands.com.

About Lightyear Capital LLC
Founded in 2000, Lightyear Capital is a financial services-focused private equity firm based in New York. Through its affiliated private equity funds, Lightyear makes primarily control investments in North America-based, middle-market companies across the financial services spectrum, including asset and wealth management, banking, brokerage, healthcare financial services, insurance, payments and processing, and specialty finance. The firm brings focus and discipline to its investment process, as well as operating, transaction and strategic management experience, along with significant contacts and resources beyond capital. For more information, please visit www.lycap.com.

About Oak HC/FT
Founded in 2014, Oak HC/FT is the premier venture growth-equity fund investing in Healthcare Information & Services (“HC”) and Financial Services Technology (“FT”). With $3.3 billion in assets under management, we are focused on driving transformation in these industries by providing entrepreneurs and companies with strategic counsel, board-level participation, business plan execution and access to our extensive network of industry leaders. Oak HC/FT is headquartered in Greenwich, CT, with offices in Boston and San Francisco. Follow Oak HC/FT on Twitter, LinkedIn, and Medium.

About Greater Sum Ventures
Greater Sum Ventures (GSV) is an entrepreneurial family office that invests its own capital in middle market software and tech-enabled services companies. With entrepreneurial roots and proven operational and investing experience, GSV works with select independent co-investing partners to build platforms of technology companies that revolutionize the industries they serve. Headquartered in Knoxville, Tennessee, GSV provides access to capital and operational support to midmarket technology firms all over the world. To learn more, visit GreaterSumVentures.com.

Media Contacts:

For Lightyear:
Elliot Sloane
(917) 291-0833
esloane@throughlineco.com

For Oak HC/FT:
Michelle Daubar
(617) 803-1707
michelle@oakhcft.com

For GSV:
Kristin Alm
(865) 850-6087
kristin.alm@greatersumventures.com

For Therapy Brands:
mediainquiries@therapybrands.com

Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures

M Ventures

SAN FRANCISCO, May 17, 2021: Soteria Biotherapeutics, Inc. (“Soteria”), a privately-held, immuno-oncology company focused on developing a next generation of switchable bispecific T-cell engagers to treat patients with solid tumor cancers, today announced a $42 million Series A financing led by Roche Venture Fund and 5AM Ventures with participation from other leading investors, including M Ventures, Novartis Venture Fund and Alexandria Venture Investments.

Soteria’s T-LITETM T-cell engagers are selectively switched on through oral administration of a small-molecule activator to modulate potent T-cell activity by controlling the timing, duration, and level of bispecific complex formation. This switchable activity enables precise on/off control over the timing and magnitude of T-cell redirection and cytotoxic activity. Unlike conventional T-cell engagers which lack a control switch and therefore are associated with significant side effects, Soteria’s T-LITE therapies are being designed to allow physicians to modulate T-cell activity to maximize efficacy while minimizing side effects.

“Soteria’s technology has the potential to revolutionize the T-cell engager field with its proprietary approach designed to control and target potent biologic immune activators to attack tumors,” said Nisha Marathe, investment director at Roche Venture Fund. “Specifically, we believe the T-LITE technology is highly differentiated, where the potent activity of a T-cell engager can be selectively switched on by small-molecule activators to direct tumor cytotoxicity and reduce cytokine release syndrome, ultimately resulting in a therapy with potentially greater safety and efficacy.”

“These funds will support the advancement of our technology and allow us to build a pipeline of T-LITE development candidates with potential in well validated cancer targets,” said Kristine Ball, chief executive officer of Soteria. “We appreciate the confidence and vision this syndicate of premier investors has shown in our opportunity to disrupt the T-cell engager field and our potential to create differentiated, potent therapies against solid tumors.”

Company Founders and Leadership
Soteria’s team of founders, management and board members brings together accomplished leaders from academia and the biopharma industry with successful track records discovering and developing therapeutics at companies such as Abgenix, Ascendis Pharma, AstraZeneca/Medimmune, Exelixis, Genentech/Roche, KAI (acquired by Amgen), Labrys (acquired by TEVA), Merck Research Laboratories, Novartis, Relypsa (acquired by Vifor) and Sunesis:

Kristine Ball, Chief Executive Officer and Member of the Board
Zachary Hill, PhD, Co-Founder and SVP, Chief Scientific Officer, and Member of the Board
Mohammad Tabrizi, PhD, VP Preclinical Development
Alex Martinko, PhD, Co-Founder and Senior Director of Protein Science
Jim Wells, PhD, Academic Co-founder, Chair of Scientific Advisory Board, and Professor of Pharmaceutical Chemistry at UC San Francisco
Steven P. James, Board Chair and Chief Executive Officer of Pionyr Immunotherapeutics
David Allison, PhD, Member of the Board and Partner at 5AM Ventures
Keno Gutierrez, PhD, Member of the Board and Vice President at M Ventures
Nisha Marathe, PhD, Member of the Board and Investment Director at Roche Venture Fund
David Morris, MD, Member of the Board and Operating Partner at Novartis Venture Fund
Momo Wu, PhD, Member of the Board and Portfolio Investment Manager at Emerson Collective

About Soteria Biotherapeutics Inc.
Soteria is developing a next generation of switchable bispecific T-cell engagers to treat cancer patients with solid tumors. Soteria’s highly innovative T-LITETM platform provides small molecule-dependent activation of bispecific antibody therapies, enabling safer and more efficacious treatments through pulsatile activity, reduced side effects and higher dosing. Soteria was founded in 2018 with technology licensed from UC San Francisco and is based in San Francisco, California. For additional information, visit www.soteriabiotherapeutics.com

Contacts:
Sylvia Wheeler
swheeler@wheelhouselsa.com
info@soteriabiotx.com

Alex Santos
asantos@wheelhouselsa.com

Press Release

Categories: News

Tags:

PerkinElmer Expands Cell Biology Leadership with Agreement to Acquire Nexcelom Bioscience

Ampersand
Highly complementary cell counting and analysis capabilities bolster preclinical portfolio and enhance QA/QC capabilities in cell and gene therapy and biologics manufacturing

PerkinElmer, Inc. (NYSE: PKI) is pleased to announce it has entered into an agreement to acquire Nexcelom Bioscience for $260 Million in cash. The transaction is expected to close during the second quarter of 2021.

Nexcelom is a leading, global provider of automated cell counting instruments, image cytometry workstations, assays and a variety of cell reagents, consumables, and fit-for-purpose cell counting method selection and development instructions that follow ISO Cell Counting Standards and aid in the development of cell and gene and immuno-oncology therapies, virology drugs and vaccines.

Headquartered in Lawrence, Massachusetts, Nexcelom is founder-led, privately held and has approximately 130 employees around the world based in the U.S., the UK and China. Nexcelom’s expected 2021 revenues are approximately $40 Million.

Commenting on the transaction, Prahlad Singh, president and chief executive officer of PerkinElmer said, “We are looking forward to bringing Nexcelom’s expertise and technologies in drug development together with our passion and solutions for drug discovery. This combination will expand our efforts to help academic, government and biopharmaceutical organizations streamline their complete workflows and support efforts to accelerate time to target and time to market for novel therapies.”

Dr. Peter Li, president and chief executive officer of Nexcelom added, “Our team is very excited to be joining forces with PerkinElmer to help scientists resolve some of today’s most pressing health challenges through modernizing cell based assays using the most advanced cell models. Our organization has a deep commitment to innovation and we are looking forward to continuing to grow our technology and customer footprint in combination with PerkinElmer’s strong global presence and infrastructure.”

PerkinElmer’s existing biologics, vaccine and cell and gene research solutions feature industry-leading high content, in vivo, and cell painting screening technologies; innovative immunoassays; CRISPR, RNAi and DNA tools and custom cell lines; cell plate readers and advanced automation; microfluidics and analytical platforms.

The agreement to acquire Nexcelom comes just five months after PerkinElmer added Horizon Discovery, a leader in gene editing and modulation. To learn more about PerkinElmer’s full range of life sciences solutions, informatics and OneSource services please visit: https://www.perkinelmer.com/corporate/what-we-do/markets/life-sciences.html.



About PerkinElmer

PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the well-being and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

About Nexcelom

Nexcelom Bioscience is a Massachusetts-based developer and marketer of image cytometry products for cell analysis in life science research and drug discovery, development and manufacturing. Products range from high performance cell viability counters (Cellometer and Cellaca) to high throughput microwell image cytometry workstations (Celigo), with turnkey solutions including instruments, consumables and reagents. Founded in 2003 and currently owned by its founders and Ampersand Capital Partners, Nexcelom delivers innovative, fit-for-purpose, accurate cell counting solutions that are critical for advanced therapeutic modalities such as cell and gene therapy. The company currently employs about 130 fast-paced, customer-centric employees who are passionate about making an impact in life science.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) effect of the COVID-19 pandemic on our sales and operations; (3) fluctuations in the global economic and political environments; (4) our failure to introduce new products in a timely manner; (5) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (6) our failure to adequately protect our intellectual property; (7) the loss of any of our licenses or licensed rights; (8) our ability to compete effectively; (9) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (10) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (11) disruptions in the supply of raw materials and supplies; (12) the manufacture and sale of products exposing us to product liability claims; (13) our failure to maintain compliance with applicable government regulations; (14) regulatory changes; (15) our failure to comply with healthcare industry regulations; (16) economic, political and other risks associated with foreign operations; (17) our ability to retain key personnel; (18) significant disruption in our information technology systems, or cybercrime; (19) our ability to obtain future financing; (20) restrictions in our credit agreements; (21) discontinuation or replacement of LIBOR; (22) the United Kingdom’s withdrawal from the European Union; (23) our ability to realize the full value of our intangible assets; (24) significant fluctuations in our stock price; (25) reduction or elimination of dividends on our common stock; and (26) other factors which we describe under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005955/en/

Contacts

Media Contact:
Jennifer McNeil
PerkinElmer, Inc.
jennifer.mcneil@perkinelmer.com
+1 508.380.2902

Investor Relations:
Steve Willoughby
PerkinElmer, Inc.
stephen.willoughby@perkinelmer.com
+1 781.663.5677

Categories: News

Tags:

Audax Private Equity to Sell Axia Women’s Health to Partners Group

Audax Group

Audax Private Equity (“Audax”) has announced that it has signed a definitive agreement to sell Axia Women’s Health to Partners Group on behalf of its clients.

Axia Women’s Health (“Axia” or the “Company”) is a leading women’s healthcare provider in the U.S. The Company is headquartered in Voorhees, New Jersey, and provides a highly integrated platform of non-clinical business and administrative support services such as accounting, HR, insurance, IT, and practice management services to its network of physician practices across the U.S. Axia partners with more than 80 care centers, comprising 150 locations and supporting 475,000 patients annually, which offer a wide range of care including obstetrics, gynecology, laboratory, mammography, urogynecology, fertility, and other women’s health sub-specialties. Axia is on the forefront of delivering women’s healthcare via an integrated model that treats patients across different phases of life, while supporting physicians’ clinical autonomy and ability to focus on care.

Since being formed by Audax in 2017, Axia has undergone a number of strategic growth initiatives:
•Expanded the continuum of care available to patients including investments in laboratory, mammography, urogynecology, fertility, and other capabilities in women’s health
•Developed value-based care programs, technology innovations, and care analytics to improve patients’ experience and outcomes
•Completed eighteen add-on acquisitions including expansion into the Midwest market, representing a significant step towards building a national platform

Charlie Choi, Chief Executive Officer of Axia, commented, “Over the last four years, Audax has supported our mission to create a more caring, connected, and progressive women’s healthcare community. Audax was instrumental in enabling growth, both organically and through acquisitions, while investing in key executive talent and systems to support long-term growth. We look forward to our next chapter with Partners Group to continue building sustainable value as a national women’s health platform.”

Adam Abramson, Managing Director at Audax, said, “We’ve enjoyed a terrific partnership with Charlie and the Axia team and are proud of the accomplishments they have made in improving women’s healthcare. We wish continued success to Axia as the Company embarks on the next phase of growth with their new partner.”

Moelis & Company LLC served as financial advisor and Ropes & Gray served as legal advisor to Axia.

Categories: News

Tags:

SYNLAB AG commences trading on the Frankfurt Stock Exchange

No Comments
Cinven

Value creation through investment in medical excellence, international expansion and consolidation

SYNLAB AG (“SYNLAB” or “the Group”), the largest European clinical laboratory and medical diagnostic services company, completed its successful listing on the Regulated Market (Prime Standard) of the Frankfurt Stock Exchange (“FSE”) on 30 April 2021. In total, 42.9 million shares were placed as part of the initial public offering. The total offer volume reached EUR 772 million with an expected free float of 19%, assuming full exercise of the Greenshoe option. At the IPO price of €18.00 per share, the implied market capitalisation was €4.0 billion, and the implied enterprise value amounted to €5.9 billion. The stock trades under the trading symbol SYAB, the German securities code (WKN) A2TSL7, and the international securities identification number (ISIN) DE000A2TSL71.

In 2015, funds advised by Cinven acquired the Germany-based SYNLAB and French medical diagnostics provider Labco at a combined enterprise value of €2.9 billion. Following the successful merger of the two companies under the joint SYNLAB brand, Cinven and co-investors Novo Holdings and Ontario Teachers’ Pension Plan Board (together “the sponsors”) supported the company on its organic and M&A-driven growth strategy. Under the leadership of Dr. Bartl Wimmer, founder of SYNLAB, and since 2018 of CEO Mathieu Floreani, SYNLAB consistently focused on a strategy of customer-centric medical excellence to drive organic growth. In a fragmented medical diagnostics market, the Group executed on more than 100 add-on transactions and expanded its presence to an additional eight countries, including market entries in Latin America and Africa. Today, the Group is active in 36 countries globally and the only player with a presence in the five largest European markets (France, Germany, Italy, Switzerland, UK). Over the past year, its scale and flexibility enabled SYNLAB to quickly ramp up SARS-CoV-2 testing capacity across its markets and contribute to fighting the COVID-19 pandemic as a key part of the medical infrastructure.

SYNLAB grew its revenues to €2.6 billion in fiscal year 2020. EBITDA increased to €679 million in the same period. In addition to its considerable business success and value creation, SYNLAB also expanded its workforce to more than 20,000 employees in 2020. The Group processes more 500 million tests and assists more than 100 million patients per annum.

Commenting on the IPO, Alex Leslie, Partner of Cinven said:

“Our original investment thesis in 2015 was based on the unique opportunity to create a European leader by combining two strong platforms with an excellent regional fit. Together with our co-shareholders, we supported the transition from a great business led by founder Bartl Wimmer to an enterprise led by a new management team under the leadership of Mathieu Floreani. Mathieu and his team built on the strong strategic position of SYNLAB and further accelerated the international expansion across markets in Europe and Latin America. We fully endorsed the strategy of customer-centric medical excellence, and we are proud that SYNLAB has played an important role in fighting the COVID-19 pandemic over the past year. SYNLAB is in an excellent position to deliver on its future growth strategy and will continue to fulfil its mission of providing actionable diagnostic information for healthy lives and well-being for all.”

Christian Salling, Senior Partner at Novo Holdings, commented:

“SYNLAB has been on an impressive journey during our ownership, and management has done an outstanding job of creating a leading, international diagnostics services provider. Furthermore, SYNLAB has been at the forefront of the fight against Covid-19 since the beginning of the outbreak and quickly stepped up to face this considerable challenge. We at Novo Holdings are very proud to be part of that journey. SYNLAB is an excellent example of our strategy of investing in quality companies with strong management teams and demonstrates the strength of our engaged ownership model, that we exercised together with leading investment partners. We are very pleased with the company’s accomplishments to date and congratulate the team on this important milestone.”

Nick Jansa, Senior Managing Director for Europe, the Middle East and Africa at Ontario Teachers’ added:

“We are delighted to see SYNLAB successfully transition to the public markets under the stewardship of Cinven, Novo and Ontario Teachers’. The business has been transformed under our ownership because of numerous strategic acquisitions and other value creation initiatives. We are proud to have backed SYNLAB, which has achieved significant growth while making a vital contribution to public health efforts across the globe.”

Categories: News

Tags:

Gimv increases its interest in German GPNZ to further support and develop the dental platform in its growth ambitions

05/05/2021 – 07:30 | Portfolio

Gimv has increased its interest in GPNZ (Gesellschaft für Praxisnachfolge in der Zahnmedizin), a fast-growing, high-quality dental platform in Germany. In addition to a significant capital increase into the company, Gimv has acquired the shares of co-investors Cannonball® and co-founder Marcus Geier. The founder and CEO of GPNZ Roman Wachtel also participated in the capital increase. The additional resources will be used to conclude further partnerships and to continue the group’s dynamic growth path. 

The dentistry group GPNZ (Gesellschaft für Praxisnachfolge in der Zahnmedizin, Munich, – www.gpnz.de) was launched in late 2018 with the aim of becoming a leading high-quality dental chain in Germany through buy and build. In collaboration with the co-investors and the current management, GPNZ has established itself as a fast growing dental platform, having assembled a group of high quality dental practices and supported them with tailor-made development plans, backed by a strong team at the Munich headquarters as well as effective regional support.

Acquisition of high quality and successful dental practices with best-in-class dentists and staff is an essential part of GPNZ’s consolidation strategy in a large but highly fragmented market, bringing benefits for dentists, staff and patients. Dentists reduce time spent on administrative, HR, marketing or commercial tasks and can focus on their medical role. They also gain flexibility in working hours and reduce their entrepreneurial risk. Staff is supported in terms of marketing, recruiting, and invoicing. Patients benefit from a wider range of professional medical services under one roof and convenience, either through additional specialisations, greater capacity or extended opening hours. Patient satisfaction and ensuring top quartile medical quality as a minimum standard in each practice are key priorities for GPNZ.

Despite the Covid pandemic, GPNZ has maintained strong momentum, with a further nine practices coming on board or having signed in the last 15 months. The company is led by an experienced management team with expertise in various healthcare fields (compliance, dentistry, marketing, hospital management, etc.) to fully support the organic growth of the practices. Long-term mutual goal alignment is ensured by management’s co-investment into GPNZ.

In the transaction announced today, co-founders Cannonball® and Marcus Geier, both having played instrumental roles in the first phase of establishing GPNZ, will sell their shares to Gimv. Gimv and CEO Roman Wachtel are committed to a further capital contribution to the company.

Philipp v. Hammerstein, Partner at Gimv, comments: “We are very pleased with the development of the group since the start of our journey back in 2018. I wish to express my sincere thanks to Cannonball®  and Marcus Geier for their invaluable contributions in establishing the company to where we stand today. We are excited about further prospects and committed to further supporting the team and developing the group going forward.”

Dominik F. Hesse, Managing Partner at Cannonball®, adds: “We are proud of having co-founded this success story and contributed significantly to building the company being both part of the management team and financial investor. It is now the right moment for us to hand over the baton. We would like to thank Gimv and the management team for this partnership and wish them all the best for the future development of GPNZ.”

Roman Wachtel, CEO of GPNZ sums up: “We are grateful for the further commitment, as well as the ongoing reliable support, deep sector knowledge and buy and build experience contributed by Gimv. We are looking forward to the future and remain fully committed to continue GPNZ’s successful path as a leading dental platform where patients experience the highest medical standards.”

This acquisition further underpins Gimv’s position as one of the most active European investors in the healthcare industry and its ambition to positively contribute to the United Nations Sustainable Development Goals of good health and well-being. Gimv currently has 23 participations in companies in the healthcare and life sciences sector. The Gimv portfolio also includes several clinic and practice groups, as well as medical technology and biotech companies.

No further financial details on this transaction are being published.

Categories: News

Tags:

Confluent Medical Announces Strategic Investment in The Electrospinning Company

Ampersand
Confluent Medical Invests in The Electrospinning Company To Expand Design Options Utilized in Structural Heart Markets

SCOTTSDALE, Ariz.–(BUSINESS WIRE)– Confluent Medical Technologies Inc. (Confluent) announced today a strategic investment in The Electrospinning Company Ltd. (Electrospinning).  Electrospinning, a UK-based company, has developed a proprietary electrospinning process which will expand the design options utilized in the structural heart market and fully automate the process of attaching biomedical textiles to heart valve frames.

Electrospinning Company productsImplant designs for the fast-growing, transcatheter structural heart market primarily utilize a custom textile that is sutured to a high-performance Nitinol metal frame.  Confluent’s Nitinol and biomedical textile expertise, in combination with Electrospinning’s leadership in electrospun nanofiber biomaterials expands the design options that Confluent customers can utilize in the structural heart market. Additionally, the application of the textile to the valve frame will be fully automated, simplifying the manufacturing process.

“The investment in Electrospinning reinforces Confluent’s strategy of Applying Materials Science to MedTech Innovation,” said Dean Schauer, CEO and President of Confluent Medical. “This partnership creates an opportunity for our two companies to facilitate further expansion of innovative structural heart products on behalf of our customers.”



About Confluent Medical Technologies

Confluent Applies Materials Science to MedTech Innovation.  Confluent’s engineered solutions to the most challenging design problems enable our OEM medical device customers to offer life-saving implantable products.  Our customers rely on Confluent for materials science and associated manufacturing expertise which is critical to the function and value of their most demanding, high growth products – proprietary expertise which spans processing of high purity Nitinol, ultra high density knitting of biomedical textiles and precision laser treatment of specialty polymers.  Confluent partners with leading OEM’s to create a selective product portfolio which includes such complex applications as transcatheter heart valves, neurovascular implants, endovascular stent grafts and advanced smart catheters.  With facilities in Fremont and Laguna Niguel, California;  Warwick, Rhode Island;  Windham, Maine;  Austin, Texas;  Chattanooga, Tennessee;  and San Jose, Cost Rica, Confluent has earned the confidence of the leaders in the medical device community through a proven track record of innovative materials science, engineering and manufacturing.  Additional information about Confluent is available at www.confluentmedical.com.

About The Electrospinning Company

Electrospinning offers contract services to design, develop and manufacture nanofiber biomaterials for medical devices and regenerative medicine. Based on the electrospinning platform technology, Electrospinning uses their expertise and experience to support clients in a range of different therapeutic indications, including the supply of the first electrospun biomaterial to be incorporated into an FDA-approved medical device. Electrospinning is located on the Harwell Innovation Campus near Oxford, UK. Additional information about The Electrospinning Company is available at www.electrospinning.co.uk.

For information please contact Confluent Medical, https://confluentmedical.com/.

Contact: Brittany Mai, Brittany.Mai@confluentmedical.com

Categories: News

Tags: